STOCK TITAN
  1. Home
  2. News
  3. VAPO

Vapotherm Inc - VAPO STOCK NEWS

Welcome to our dedicated news page for Vapotherm (Ticker: VAPO), a resource for investors and traders seeking the latest updates and insights on Vapotherm.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vapotherm's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vapotherm's position in the market.

News
Onymos and Vapotherm Announce Partnership to Create an End-to-End Internet of Medical Things Solution (IoMT)
Rhea-AI Summary
Vapotherm partners with Onymos to accelerate the development of a respiratory digital platform for HVT® 2.0 and future home products. The partnership aims to enhance data visualization and device management, leveraging IoT features to connect devices with the cloud. This collaboration enables Vapotherm to offer innovative solutions for improved patient outcomes and operational efficiency in medical settings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
partnership
-
News
Vapotherm to Unveil Access365 Home Ventilation Solution at MEDTRADE
Rhea-AI Summary
Vapotherm, Inc. introduces Access365™ Home Ventilation Solution at MEDTRADE conference, aiming to enhance the quality of life for hypercapnic patients. The device offers innovative features to reduce hospital readmissions and improve patient care, including a built-in humidifier, Bluetooth pulse oximetry, and spirometry. Vapotherm expects FDA clearance in early 2025, positioning itself as a leader in home ventilation solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.49%
Tags
none
-
News
Dr. David Yamane was awarded the Star Research Award at the 2024 Critical Care Congress for the presentation of the HYPERACT Study - a randomized controlled trial demonstrating Vapotherm's High Velocity Therapy effectively treats moderate-severe acute exacerbations of COPD, while improving patient comfort
Rhea-AI Summary
Vapotherm, Inc. (VAPO) announces Dr. David Yamane's Star Research Award for the HYPERACT study at the 2024 Critical Care Congress. The study introduces high velocity therapy as a more comfortable option for COPD treatment, comparing it to NiPPV.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
none
News
Vapotherm's HVT 2.0 System Overcomes Regulatory Hurdles for Entry into South America's Largest Health Care Market
Rhea-AI Summary
Vapotherm, Inc. announces regulatory approval of HVT 2.0 system in Brazil, tapping into a growing market for respiratory devices. The company aims to address the increasing demand for COPD treatment in the country.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Vapotherm Reports Fourth Quarter and Fiscal Year 2023 Financial Results
Rhea-AI Summary
Vapotherm, Inc. announces strong financial results for Q4 2023 and FY 2023, showing revenue growth, margin improvement, and cost reduction. The HYPERACT clinical trial results were also positive, indicating the therapy's effectiveness in COPD patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.6%
Tags
earnings
-
News
Vapotherm Announces Suspension of NYSE Listing Common Stock Expected to Begin Trading Promptly on OTCQX
Rhea-AI Summary
Vapotherm, Inc. (NYSE: VAPO) received notice of suspension and delisting of its common stock by the New York Stock Exchange due to falling below the listing standard of $15 million average global market capitalization. The company's stock is expected to begin trading on the OTCQX Market on December 15, 2023, under the symbol VAPO. Vapotherm reassures investors of continued access to accurate information and trading. The change does not impact the company's business or profitability initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.05%
Tags
none
News
Vapotherm Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock Application Pending to Transfer Shares to OTCQX
Rhea-AI Summary
Vapotherm, Inc. (NYSE: VAPO) announces voluntary delisting from NYSE and filing for OTCQX Marketplace
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.86%
Tags
none
-
News
Vapotherm Educates over 8,000 Clinicians in Respiratory Care Month
Rhea-AI Summary
Vapotherm, Inc. (NYSE: VAPO) announces the participation of over 8,000 clinicians in digital-based respiratory education. Dr. Jessica Whittle, Chief Medical Officer, expressed excitement for the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.08%
Tags
none
-
News
Vapotherm Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Vapotherm, Inc. (NYSE: VAPO) announced third quarter 2023 financial results, with net revenue of $15.2 million, a 12.0% increase from Q3 2022. Non-GAAP net revenue, excluding Vapotherm Access, increased by 17.6%. Gross margin was 39.6%. The HYPERACT clinical trial results will be presented at the Society for Critical Care Medicine Congress in January 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.27%
Tags
earnings
News
Vapotherm To Report Third Quarter 2023 Financial Results
Rhea-AI Summary
Vapotherm, Inc. will release its financial results for Q3 2023 on November 8, 2023. The management team will host a conference call to discuss the results and recent business developments. Investors can listen to the call via telephone or a live webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
conferences earnings
Stock VAPO logo
Vapotherm Inc

OTC:VAPO

VAPO Rankings

N/A Ranked by Market Cap
#5333 Ranked by Stock Gains
N/A Ranked by Dividends

VAPO Stock Data

9.91M
2.93M
16.79%
42.95%
7.69%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Exeter

About VAPO

vapotherm develops and manufactures innovative, comfortable, noninvasive technologies for respiratory support of patients with chronic or acute breathing disorders. over 1 million patients have been successfully treated with vapotherm hi-vni technology, and the number is growing rapidly every day. we have an unrelenting commitment to improving patient lives, significant sales growth, a dynamic and exciting work environment, and a focus on hiring and developing the very best people in the medical device industry. now is a great time to join our growing team. vapotherm is a privately held company located in exeter, new hampshire. for more information, visit www.vapotherm.com.